AOD-9604 research centers on a deceptively simple question: can the fat-mobilizing "message" of human growth hormone be isolated from the rest of the GH signal? AOD-9604 is a synthetic analog of the C-terminal region of human growth hormone, corresponding to amino acid residues 176–191 (hence the name "hGH fragment 176-191"), with a tyrosine residue added at the N-terminus to improve stability. In laboratory and in-vitro settings, this fragment is studied specifically because it appears to reproduce the lipolytic activity of the parent hormone while, in the preclinical literature, showing little or no engagement of the growth-hormone receptor and its downstream IGF-1 axis. That dissociation is the entire scientific angle of this guide.
Research Use Only (RUO): AOD-9604 is supplied strictly for laboratory research use only. It is not for human or veterinary use, is not a drug or dietary supplement, and has not been evaluated by the FDA. Nothing here is intended to diagnose, treat, cure, or prevent any disease. All statements describe mechanisms and published in-vitro/preclinical findings for scientific and educational purposes only.
What Is the hGH 176-191 Fragment?
Full-length human growth hormone (191 residues) is a pleiotropic hormone: it drives longitudinal growth, protein synthesis, and hepatic IGF-1 output, and it modulates lipid and carbohydrate metabolism. Structure–function studies in the 1990s mapped the hormone's lipolytic domain to a short C-terminal stretch. Isolating residues 176–191 produced a peptide that retained the fat-mobilizing signal while shedding the somatogenic (growth-promoting) and diabetogenic activities associated with the intact molecule. AOD-9604 ("Anti-Obesity Drug 9604") is the stabilized version of that fragment developed for metabolic research.
Sequence and physical properties
- Origin: C-terminal region of hGH (residues 176–191) plus an added N-terminal tyrosine.
- Approximate molecular weight: ~1.8 kDa (a 16–17 residue peptide).
- Class: Peptide fragment / GH analog studied as a metabolic research compound.
- Research framing: Investigated as a lipolytic signal decoupled from the GH–IGF-1 growth axis.
The Central Angle: Lipolytic Signaling Without the GH-Axis IGF-1 Response
What makes AOD-9604 a distinct object of study is not simply that it may promote lipolysis — many agents do — but how it appears to do so. Full-length GH signals through the growth-hormone receptor (GHR), triggering JAK2/STAT5 activation and, in the liver, transcription of IGF-1. IGF-1 in turn mediates most of GH's proliferative and growth effects and is implicated in the hormone's less desirable metabolic consequences, such as insulin resistance at high exposure.
In preclinical models, AOD-9604 has been reported to stimulate lipolysis and inhibit lipogenesis without measurably raising IGF-1 and without the receptor-mediated proliferative signaling characteristic of intact GH. This is the property researchers try to exploit: a way to interrogate fat-cell metabolism using a GH-derived signal while holding the confounding IGF-1 variable near baseline. For a deeper mechanistic treatment, see our AOD-9604 & Lipolysis: Mechanism Explainer.
Proposed mechanism in the literature
Research models describe a dual, largely GHR-independent pathway:
- Acute lipolytic signaling. AOD-9604 is associated with increased activity of hormone-sensitive lipase (HSL), the enzyme that hydrolyzes stored triglycerides into free fatty acids and glycerol. In classic adrenergic lipolysis, this step is downstream of adenylate cyclase, elevated cyclic AMP, and protein kinase A.
- β3-adrenergic receptor involvement. Chronic exposure in adipocyte and rodent models has been reported to upregulate β3-adrenergic receptor (β3-AR) expression in adipose tissue, a receptor strongly tied to fat oxidation and thermogenesis. This offers a plausible route to sustained fat mobilization that does not require GHR occupancy.
- Suppressed lipogenesis. Alongside promoting breakdown, the fragment has been described as reducing the enzymatic machinery of fat storage, shifting the adipocyte's net balance toward mobilization in these models.
The net picture from in-vitro work: a fat-cell signal that raises cAMP/HSL-type lipolytic tone and reshapes β3-AR density, while leaving the STAT5–IGF-1 growth arm comparatively untouched.
Why the IGF-1 Decoupling Matters for Study Design
For a research group modeling adipose metabolism, IGF-1 is a noisy variable. A compound that appears to move lipolytic endpoints without shifting IGF-1 lets investigators attribute observed changes to lipid-handling pathways rather than to systemic growth-factor effects. This is also the axis on which AOD-9604 is most often contrasted with GH-secretagogue-style approaches such as tesamorelin, which act upstream on GH release and therefore do engage the IGF-1 axis. That comparison is explored in AOD-9604 vs Tesamorelin: Fat-Research Compared.
It is worth noting for scientific honesty that AOD-9604's clinical development program (six trials, roughly 900 participants) established a favorable safety profile but did not demonstrate the hoped-for weight-loss efficacy in humans, and development was discontinued. In the research context this makes AOD-9604 a valuable mechanistic tool and a cautionary case study in translating in-vitro lipolysis to whole-organism outcomes — not evidence of any human benefit.
Where AOD-9604 Sits in the Metabolic Peptide Landscape
AOD-9604 is frequently grouped with metabolic research peptides, though its mechanism is distinct from the incretin-based compounds. Unlike GLP-1 receptor agonists, which act on satiety, gastric emptying, and insulin secretion, the hGH fragment targets the adipocyte lipolysis machinery directly. For orientation to the incretin side of this landscape, see our GLP-1 in Research: Incretin Peptide Overview, and the parent hub, Metabolic & GLP Research Peptides.
| Attribute | AOD-9604 (hGH 176-191) | GLP-1 class (research context) |
|---|---|---|
| Primary target | Adipocyte lipolysis (HSL, β3-AR) | GLP-1 receptor (incretin axis) |
| GH / IGF-1 engagement | Minimal in preclinical models | Not applicable |
| Proposed action | Fat mobilization, reduced lipogenesis | Satiety, glucose-dependent insulin |
| Research framing | Lipolysis without growth-axis noise | Metabolic / glycemic modeling |
Laboratory Handling of AOD-9604 Research Preparations
The following is general guidance for handling lyophilized research peptides in a laboratory setting — not a use protocol.
- Storage (lyophilized): Keep sealed vials cold and protected from light; long-term storage is typically at −20 °C. Short transit at ambient temperature is generally tolerated for stable peptides.
- Reconstitution: Bacteriostatic or sterile water is commonly used to prepare research stock solutions; the diluent is directed slowly down the vial wall rather than onto the powder to limit shear.
- Post-reconstitution: Refrigerate reconstituted solutions (typically 2–8 °C) and record the preparation date. Avoid repeated freeze–thaw cycles, which degrade peptide integrity.
- Documentation: Verify identity and purity against the batch Certificate of Analysis (COA) before experimental use.
Sourcing for Research
NeuroLabs supplies AOD-9604 5mg at ≥99% purity, third-party COA-tested, with same-day USA shipping for laboratory research. For a purchasing-focused overview, see Where to Buy AOD-9604 Research Peptide (USA). Questions on COA documentation or orders can be directed to neurolabsresearch3@gmail.com.
Frequently Asked Questions
What does "hGH fragment 176-191" mean?
It refers to the segment of the human growth hormone molecule spanning amino acid residues 176 through 191, the region mapped to GH's lipolytic activity. AOD-9604 is a stabilized synthetic version of this fragment used in metabolic research.
Why is AOD-9604 studied separately from full-length GH?
Because in preclinical models it appears to reproduce GH's fat-mobilizing signal without engaging the growth-hormone receptor's proliferative, IGF-1-generating pathway. This lets researchers isolate lipolytic signaling from the broader growth axis.
Does AOD-9604 raise IGF-1 in research models?
The published preclinical literature reports little or no increase in IGF-1, which is precisely why it is used as a tool to study lipolysis independently of GH-axis growth-factor effects. Findings are model-dependent and described for research contexts only.
Is AOD-9604 approved for any human use?
No. It completed clinical trials that showed good safety but did not meet weight-loss efficacy endpoints, and it is not an approved drug. It is offered strictly for laboratory research use only and is not for human or veterinary use.
How is AOD-9604 stored in the lab?
Lyophilized vials are kept cold and dark (typically −20 °C long-term); reconstituted solutions are refrigerated and protected from repeated freeze–thaw cycles. Always confirm identity and purity against the COA.